Raymond Haward

Dr. Raymond Haward


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2024 in Cureus
Verified
Journal Article
Open access
RNRahul Navab
Rahul Navab
RHRaymond Haward
Raymond Haward
JCJoshua Chacko
Joshua Chacko
RHRachel Haward
Rachel Haward
Globally, one of the primary factors leading to death is cardiovascular disorders, specifically coronary artery disease, which leads to myocardial infarction (MI). This article investigates the potential of platelet -rich plasma (PRP) therapy for regenerating cardiac cells following MI. We look into the pathophysiology of MI, current treatment methods, and the heart's limited ability to heal itself. This is done to see if PRP could help the heart heal faster, reduce the size of the infarct, and stop scar tissue from forming. We analyze the production procedure of PRP, its composition of growth factors, and its utilization in many medical domains. The ways that PRP helps the heart heal are also being looked into. This includes how it affects inflammation, oxidative stress, angiogenesis, and cell proliferation. Although we recognize the existing constraints, we meticulously take into account issues such as standardization, therapeutic variance, and potential harmful effects. This study highlights the importance of comprehensive guidelines, continuous research, and enhanced clinical applications to fully harness the potential of platelet -rich plasma in the regeneration of cardiac cells after a heart attack.

18 December 2023 in Cureus
Verified
Journal Article
Open access
PDF file
RHRaymond Haward
Raymond Haward
RHRachel Haward
Rachel Haward
JSJ V Pranav Sharma
J V Pranav Sharma
Drug reaction with eosinophilia and systemic syndrome (DRESS) is a life-threatening hypersensitivity reaction of the skin and visceral organs caused by exposure to certain drugs, often with a latency period of two to eight weeks. A 20-year-old man, previously diagnosed with pulmonary tuberculosis (TB) one month ago and receiving treatment with isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE regimen), presented with symptoms including a maculopapular rash, fever, elevated transaminase levels, an increased white blood cell count with eosinophilia, hepatomegaly, and lymphadenopathy. The patient experienced recovery upon cessation of drug use and was administered corticosteroids and supportive therapeutic interventions. Individuals diagnosed with pulmonary TB who are undergoing treatment with first-line anti-tubercular medications have a heightened susceptibility to DRESS. The timely identification and cessation of the offending agent can effectively mitigate mortality.

20 November 2025 in Journal of Biological Methods
Verified
Journal Article
Open access
PDF file
RIRidah Ijaz
Ridah Ijaz
RHRaymond Haward
Raymond Haward
Background: Cardiovascular diseases remain the leading cause of mortality globally, driven largely by modifiable risk factors, such as hyperlipidemia, hypertension, diabetes, and oxidative stress. As conventional pharmaceutical interventions often carry adverse effects and economic burdens, there is growing interest in alternative therapies. Objective: This narrative review explores vinegar, a traditional remedy with historical and cross-cultural usage, as a potential adjunct in cardiovascular health management. Vinegar contains a rich array of bioactive compounds, including acetic acid, polyphenols, amino acids, melanoidins, and tetramethylpyrazine, which may exert antioxidant, anti-inflammatory, lipid-lowering, antihypertensive, and antithrombotic effects. Preclinical studies in animal models and limited human trials indicate promising outcomes in improving lipid profiles, blood pressure regulation, glycemic control, and endothelial function. Despite these benefits, there is a paucity of large-scale, high-quality human studies to validate vinegar’s clinical efficacy and safety. Conclusion: This review underscores the potential of vinegar as a functional food with cardioprotective properties and advocates for further rigorous research to establish standardized dosing, isolate active constituents, and assess long-term outcomes in human populations.

18 September 2026 in Medicine
Verified
Journal Article
Open access
RHRaymond Haward
Raymond Haward
NDNikhil Duseja
Nikhil Duseja
HSHarkanwar Sandhu
Harkanwar Sandhu
SBShankar Biswas
Shankar Biswas
JMJai Kumar Rajavoor Muniswamy
Jai Kumar Rajavoor Muniswamy
SKSwathi Deepak Kulkarni
Swathi Deepak Kulkarni
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuronal loss and α-synuclein aggregation, resulting in motor dysfunction and increasing mortality. Chronic kidney disease (CKD), affecting nearly 700 million people worldwide, is associated with systemic inflammation, vascular dysfunction, and excess mortality. Emerging evidence suggests a bidirectional relationship between CKD and PD, with renal impairment potentially accelerating neurodegeneration and worsening clinical outcomes. This study examined national mortality trends among individuals with coexisting PD and CKD in the United States from 1999 to 2023. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. Mortality data were obtained from the CDC WONDER database. Deaths listing both PD (International Classification of Diseases, Tenth Revision [ICD-10]: G20) and CKD (ICD-10: N18) were identified. Age-adjusted mortality rates (AAMRs) per 1,00,000 population were standardized to the 2000 US population and stratified by year, sex, region, and urban-rural status. Joinpoint regression estimated Annual percent change (APC), with P < .05 considered statistically significant. Between 1999 and 2023, 20,437 deaths were attributed to coexisting PD and CKD. National AAMR increased more than 4-fold, from 0.1 to 0.5 per 1,00,000 (APC = 5.23; 95% CI: 3.92–6.55). Mortality increased in females (0.1–0.3; APC = 5.15; 95% CI: 3.35–6.99) and males (0.2–0.8; APC = 4.79; 95% CI: 3.57–6.02). All census regions demonstrated significant increases, with the greatest rise in the West (APC = 5.92; 95% CI: 4.22–7.64). Mortality also increased in both urban (APC = 5.01) and rural (APC = 4.78) populations. Mortality among individuals with coexisting PD and CKD has risen substantially across demographic and geographic groups in the United States over the past 2 decades. These findings highlight the need for integrated neurology-nephrology care, early recognition of renal dysfunction, and targeted risk-factor management. Further research is warranted to clarify underlying mechanisms and develop strategies to reduce mortality in this high-risk population.

14 October 2026 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
HSHarkanwar Sandhu
Harkanwar Sandhu
NDNikhil Duseja
Nikhil Duseja
RHRaymond Haward
Raymond Haward
MSMuhammad Faizan Shaikh
Muhammad Faizan Shaikh
Newton Ashish ShahNewton Ashish Shah
Newton Ashish Shah
SBShankar Biswas
Shankar Biswas
Background: Diabetes mellitus and sepsis are major contributors to morbidity and mortality in the United States. Diabetes-related immune dysfunction increases susceptibility to infection and sepsis, yet national trends in combined diabetes–sepsis mortality remain insufficiently characterized. Objective: To examine long-term mortality trends and demographic disparities associated with diabetes and sepsis across all age groups in the United States from 1999 to 2023. Methods: Mortality data were obtained from the CDC WONDER database using ICD-10 codes E10–E14 (diabetes) and A41 (sepsis). Crude and age-adjusted mortality rates (AAMRs) per 100 000 population were calculated and stratified by sex, race/ethnicity, U.S. Census region, and urban–rural status. Joinpoint regression was used to estimate annual percent change (APC) with 95% confidence intervals (CIs). Results: From 1999 to 2023, 479 661 deaths were attributed to diabetes and sepsis. AAMRs declined significantly through 2018, followed by a sharp increase during 2018–2021, and a subsequent decline through 2023. Mortality was consistently higher among males than females, with both groups experiencing pandemic-related spikes. Black, Hispanic, and American Indian/Alaska Native populations showed greater mortality fluctuations than White and Asian or Pacific Islander populations. Rural areas had persistently higher mortality than urban areas. The South and West regions experienced the largest increases during 2018–2021. Conclusion: Although long-term mortality from diabetes and sepsis has declined, the pandemic-era surge highlights the vulnerability of high-risk populations during healthcare disruptions. Targeted public health strategies emphasizing chronic disease management and equitable healthcare access are essential to sustain progress and mitigate future mortality surges.

3 April 2026 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
RHRaymond Haward
Raymond Haward
RHRachel Haward
Rachel Haward
Newton Ashish ShahNewton Ashish Shah
Newton Ashish Shah
SBShankar Biswas
Shankar Biswas
JCJoshua Chacko
Joshua Chacko
Background: Emphysema is a global threat causing significant mortality and economic burden. Risk factors like smoking, secondhand smoke, vaping, and pollutants are strongly linked to the progression and mortality of emphysema. Objective: The study analyzed demographic trends and disparities in mortality rates due to emphysema among all age groups from 1999 to 2023. Methods: We used the CDC WONDER database to analyze age-adjusted mortality rates (AAMRs) for emphysema (ICD-J43 from 1999 to 2023), stratifying by year, sex, race, and census region. We calculated annual percentage changes per 100 000 with 95% confidence intervals using Joinpoint regression. Results: A total of 548 467 emphysema-related deaths were recorded in the United States between 1999 and 2023. National age-adjusted mortality rates (AAMRs) showed significant declines from 1999 through 2015, followed by a reversal with increasing rates through 2023. Males consistently exhibited higher mortality than females, though both experienced substantial reductions before subsequent increases in the last decade. Ethnic disparities were evident: non-Hispanics had persistently higher mortality than Hispanics, with the latter showing overall lower rates and largely sustained declines. Regional analysis revealed the Midwest as bearing the highest mortality burden, followed by the West, South, and Northeast. All regions demonstrated early declines in mortality, with later upturns emerging after 2015, most prominently in the South and West. Conclusion: This study reveals that strict antismoking campaigns and health education must be further implemented to reduce mortality rates related to emphysema. These findings emphasize the need for further targeted interventions, awareness, and improved access to care to reduce mortality from emphysema.